to the globus pallidus and substantia nigra, and reactive gliosis occurs as neurons are lost. The cortex is also markedly atrophied in the later stages of the disease, although it is unclear whether this is a secondary effect arising because of the striatal atrophy. HD brains are significantly lighter at death than equivalent control brains (Neal et al 1994) . MacMillan and Quarrel (1996) give a detailed review of the neurobiology of HD.
HD was one of the first diseases for which genetic mapping was attempted and many of the techniques currently used in gene mapping were originally applied in the HD mapping project. Mapping began in 1983 and was a truly collaborative effort, leading to the isolation of the gene in 1993 by the Huntington's Disease Collaborative Research Group (1993) . The associated mutation proved to be an expanded CAG trinucleotide repeat: in the normal population this repeat is polymorphic with a size range of 8-39 CAG; in the affected population the repeat is expanded to 36-121 CAG (Huntington's Disease Collaborative Research Group 1993; Rubinsztein et al 1996) . There are a number of diseases caused by expansions of trinucleotide repeats. Fragile X, myotonic dystrophy and Friedreich's ataxia have repeats in noncoding sequence (Aslanidis et al 1992; Buxton et al 1992; Harley et al 1992; Mandel and Heitz 1992; Hirst et al 1993; Knight et al 1993; Campuzano et al 1996) . Spinal and bulbar muscular atrophy (Kennedy disease), HD, dentatorubral pallidoluysian atrophy, Machado-Joseph disease and spinocerebellar ataxia 1 are all caused by CAG repeats translated to give a polyglutamine tract (Ross 1995; and see Fischbeck 1997) . Perhaps the most interesting characteristic of this latter type of trinucleotide repeat disease is the similarity between the normal and disease-causing repeat lengths.
Analysis of the HD gene sequence showed it to span 180kb of genomic DNA, with 67 exons giving 9.5kb coding sequence . The repeat occurs in exon 1 and is translated into protein (DiFiglia et al 1995; Jou and Myers 1995; Schilling et al 1995; Trottier et al 1995a) giving a polyglutamine tract close to the N-terminus of a 350kDa protein, huntingtin. Huntingtin has no functional homologies in the databases and thus its normal cellular role remains unclear.
GENETIC ANALYSIS
Once the gene was cloned, many workers correlated phenotypic characteristics of the disease with repeat length. The most obvious correlation is that of age of onset, where around half of the variability in age of onset can be attributed to an inverse correlation with length of the expanded CAG repeat (Figure 2 ). In fact, upon closer examination, it is clear that for juvenile cases this correlation is strong, but for adult-onset cases (the majority) it is much weaker (Andrew et al 1993; Duyao et al 1993; Snell et al 1993) . This, together with the area between 36 and 39 repeats where predictions of final HD status cannot be
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J. Inher. Metab. Dis. 20 (1997) Figure 2 Correlation of age at onset of HD with repeat length. Data taken from the Welsh population (Snell et al 1993) made (Rubinsztein et al 1996) , indicates that there are other factors influencing onset of degradation and neurological symptoms. One of the first effects of isolation of the mutation was the availability of a definitive genetic test. Members of affected families can now have their risk status clarified, and prenatal testing is also possible. However, most people at risk for HD do not choose to be tested and, as no therapy is currently available, there are no obvious direct benefits to knowing that the gene carrying the expansion is present. This is an issue that has aroused a great deal of interest in both the scientific and lay literature, and is discussed at length in .
EXPRESSION OF THE HUNTINGTON DISEASE GENE, hdh
Expression of hdh appears ubiquitous in humans and there are two main transcripts, of 13.5 and 10.5kb, both of which are present in most tissues, although the larger transcript is more abundant in brain. Expression of the mouse and rat homologous genes (mhd and rhd respectively) is similar to that of the human gene in both transcripts produced and localization, although in mouse there is evidence for a further transcript of 12kb which may arise from alternative splicing of the gene (Huntington's Disease Collaborative Research Group 1993; Strong et al 1993; Barnes et al 1994; Lin et al 1994; Schmitt et al 1995) . There is no evidence for alternative splicing of hdh in humans. Landwehrmeyer and colleagues (1995) carried out a systematic survey of hdh expression in human brain, using in situ hybridization, and concluded that there was little difference in expression in normal and HD brain, other than that which could be accounted for by tissue loss in the striatum. Expression was highest in cortical layers II-IV, the hippocampus and dentate gyrus, but only moderate in the areas of the basal ganglia that degenerate first in HD.
PATHOGENESIS IS AT THE PROTEIN LEVEL
Production of protein is essential for the disease process, and the protein produced is pathogenic. A transgenic mouse that produces mRNA from an expanded human huntingtin gene fails to produce protein and is phenotypically normal (Goldberg et al 1996) . Mice expressing protein from a SCA1 transgene with 82 CAG driven by a Purkinje cell-specific promoter developed ataxia in a dose-dependent manner, whereas those with a similar construct with only 30 CAG remained normal (Burright et al 1995) .
The toxicity of expressed polyglutamine regions has been demonstrated recently in transgenic mice and in cell culture. Ikeda and colleagues (1996) expressed the human Machado -Joseph gene as a transgene in mice and also in cell culture and found that its toxicity was mediated by the amount of coding sequence around the repeat. The most toxic constructs were those with only the repeat and no surrounding sequence. Similarly, Mangiarini and colleagues (1996) have produced mice carrying a transgene of the HD gene promoter sequence and only exon 1 of the coding region, with CAG expansions of 115-150 repeats. These mice have a neurological phenotype, including a movement disorder, high calorific requirements and handling-induced fits and are small compared with normal littermates. The cause of their early death is unknown and there is no obvious pathology. Again, there appears to be a dose-dependent effect, with longer repeats and more transgene insertion events causing earlier onset of abnormalities. These fascinating results allow the conclusion that polyglutamine is toxic to cells, and that this toxicity is mediated in the trinucleotide repeat diseases by the rest of the protein in which the repeat occurs. The specificity of degeneration in these diseases may be mediated by the inter-actions of the polyglutamine-containing proteins with other cellular proteins. The expan-sion may give rise to abnormal interactions in specific cell types, or normal interactions of huntingtin specific to certain cells may be protective against the toxic effects of the expansion.
INTERACTIONS OF HUNTINGTIN
Huntingtin has been shown to have interactions with at least four other proteins. The first interaction reported was that of Li and coworkers (1995) who used the yeast two-hybrid system and found an interaction of an unknown 70kDa protein, HAP1 (huntingtinassociated protein 1), with the N-terminus of huntingtin. Expression of HAP1 is brainspecific and colocalizes with NO synthase neurons (Li et al 1996) . Huntingtin and other polyglutamine containing proteins interact with glyceraldehyde phosphate dehydrogenase (GAPDH) (Burke et al 1996) . GAPDH is ubiquitous and, apart from being a glycolytic enzyme, also has functions in microtubule bundling (Huitorel and Pantaloni 1985) , DNA repair (Siegler et al 1991) and endocytosis (Robbins et al 1995) . Huntington has an indirect interaction with calmodulin in the presence of calcium (Bao et al 1996) . The above interactions are all stronger as the length of the polyglutamine tract increases. Huntingtin also interacts with a ubiquitin-conjugating enzyme which is highly expressed in brain , although this interaction is not modulated by polyglutamine tract length.
The relevance of any of these interactions to the normal or pathogenic function of huntingtin is unclear. Many proteins are degraded via the ubiquitin pathway. GAPDH is an abundant protein found in all cells and its interaction with huntingtin is relatively weak, compared with the interaction of other disease-causing polyglutamine-containing proteins; this may indicate a relatively nonspecific polyglutamine binding. HAP1 has, at present, no known function or homologies and calmodulin is an intermediate in many Ca 2+ -mediated signalling pathways.
LOCALIZATION OF HUNTINGTIN
Two main techniques have been used in the examination of huntingtin localization: tissue fractionations and immunohistochemistry. Many groups have made anti-huntingtin antibodies and carried out such experiments. Human huntingtin is associated with membrane fractions from brain tissue and colocalizes in fractionations with synaptophysin, a synaptic vesicle membrane inserted protein (DiFiglia et al 1995; Sharp et al 1995; Wood et al 1996) . However, mouse huntingtin is mostly found in the soluble fraction, and rat huntingtin is distributed between both fractions (Figure 3 and Wood et al 1996) . The human fractionation in Figure 3 also demonstrates quite clearly that products of different sizes are produced, corresponding to the products of the normal and expanded alleles. Some workers report the expanded allele to be more strongly immunostained (Aronin et al 1995) , while others report the normal allele to be so, as here (DiFiglia et al 1995; Schilling et al 1995) . This may depend on repeat length studied (Aronin analysed juvenile cases with very long repeats) and on the antibody used: the exposure of different epitopes may be affected by the expansion.
Localization in human and rodent brain shows huntingtin immunoreactivity which is greatest in those areas where expression is highest (Figure 4 ; DiFiglia et al 1995; Gutekunst et al 1995; Sharp et al 1995) . There appears to be general cell body staining in cortical neurons, in contrast with the rather punctate staining seen in the caudate. Figure 4 shows this quite clearly in murine brain. There is also strong cell body staining of the Purkinje cells in the cerebellum, and in the hippocampus and dentate gyrus. There have been no reports of a differential localization of huntingtin in normal and HD brain. However, we have recently carried out a preliminary immunohistochemical study on postmortem HD and normal brain, in formalin-fixed and snap-frozen post-mortem brain sections. The results are essentially the same in both, although the poorer preservation of the frozen tissue makes these immunolocalizations less easy to interpret; the results presented in Figure 5 show rehydrated paraffin wax sections. Figures 5a and 5b show HD and normal caudate. The HD caudate is Von Sattel grade 3 with severe atrophy, few neurons are visible and the remaining tissue consists mostly of glial cells. The staining occurs fairly uniformly in the cytoplasm of reactive astrocytes. In HD and normal cortex there is little staining and no visible difference between HD and normal tissue, whilst in the cerebellum there is more staining of the HD than normal cerebellum in the granule layer. heritable forms (Van Broekhoven 1995); PD is rare, but may also have a heritable component. Pathologically AD is characterized by neurofibrillary tangles and neuritic plaques with specific antigenic determinants, including β-amyloid, although the relationship of these pathological entities to the clinically observed dementia is unknown (Hardy and Higgins 1992; Iwatsubo et al 1994; Kosik et al 1986; Roses 1994) . PD is characterized by Pick bodies within neurons, which have similarities to AD neurofibrillary tangles but without the amyloid involvement (Love et al 1988) . The pathological deposits in both of these diseases appear to involve abnormal cytoskeletal elements (Arai et al 1990; Yasuhara et al 1995) . In AD huntingtin immunolocalizes with neuritic plaques (Figure 5c ), neurofibrillary tangles ( Figure 5d ) and dystrophic neurites, and in PD with Pick bodies (Figure 5e ). It appears then, that huntingtin is found in areas of pathology in HD and other neurodegenerative diseases. Does this provide us with any further clues to the disease 132
Jones et al. J. Inher. Metab. Dis. 20 (1997) Figure 5 In order to consider this question, it is helpful to examine the theories of degeneration proposed to occur in HD. These can be divided into theories already proposed before the gene was localized, based on the known pathology and physiology of HD, and those informed by the knowledge of the gene and its mutation.
THEORIES OF DEGENERATION
Before isolation of the gene, several theories based on the known pathology and clinical symptoms of the disease were proposed, including neuronal death through the effects of exitotoxic amino acids, defects in energy metabolism or oxidative damage caused by reactive oxygen species. The evidence for and against these theories is given in detail in Beal (1995) . The neurons lost initially in HD are striatal interneurons and γ-aminobutyric acid (GABA)-ergic neurons with efferents to the globus pallidus. These include NMDAreceptor neurons; opening of the NMDA (N-methyl-D-aspartate-activated) channels allows influx of Ca
2+
. These receptors are gated by glutamate, with glycine and Mg 2+ also involved in their control Ascher 1990, Watkins et al 1990) , and increases in the level of glutamate remove the Mg 2+ blockade of the NMDA channel and allow Ca 2+ influx, which is known to cause a cascade of events downstream (Coyle and Puttfarcken 1993, and Figure 6 ). Reduced energy metabolism will depolarize the cell by reducing Na + ,K + -ATPase activity, and this too will lead to Ca 2+ influx ( Figure 6 ). Extracellular glutamate is cleared by glutamate transporters and these are Na + -dependent; thus glutamate reuptake will also be affected, leading to a further increase in glutamate concentrations (Nicholls and Atwell 1990) . All these effects can be interlinked (Figure 6 ), and it is probable that several are occurring in HD, although how they are propagated initially by the expanded glutamine tract is unknown.
The glutamine expansion itself may be responsible for the formation of abnormal protein structures. Green (1993) suggested that transglutaminases may cross-link the glutamines in the tract with lysine residues in other proteins, leading to the formation of protease resistant γ-glutamyl (ε-lysyl) cross-links and isodipeptides. Transglutaminases are expressed increasingly with age, and the cross-linking of lysine-containing proteins may lead to cellular dysfunction and cell death.
Perutz Perutz 1994) has suggested that polyglutamine may form a polar zipper, as glutamine is a polar amino acid with an amide group at the end of its sidechain; the glutamine tracts could then interact through hydrogen bonds between the mainchain and side-chain amide groups. Experimental work with synthetic peptides and expression of glutamine tracts in bacteria indicates that such zippers do form in vitro (Stott et al 1995) . Their presence in vivo remains to be demonstrated, but the visibility of huntingtin-positive cells in post-mortem HD caudate, which did not occur in control caudate (Figure 5a,b) suggest that huntingtin is forming a complex that is resistant to degradation. The presence of huntingtin in AD and PD pathological inclusions (5c -e) suggests that this protein, in its normal unexpanded form, is capable of being complexed in abnormal inclusions. This must be secondary to the initial events of deposition of such inclusions in AD and PD, but may be the primary event in HD, where the protein carries the expanded polyglutamine region, leading to further damage through as yet unknown pathways. There is evidence that the expansion leads to the presence of a novel epitope in huntingtin and other proteins that carry expanded repeats (Trottier et al 1995b) , implying a conformational shift at around the threshold number of glutamines leading to disease. In AD and PD the intracellular inclusions seem to be made up largely of abnormal cytoskeletal proteins (Love et al 1988; Yasuhara et al 1995) , and huntingtin too is associated with microtubules ( Figure 7) . As already mentioned, GAPDH is associated with microtubules and is a microtubule bundling protein; it also interacts with the cytoplasmic tail of the Alzheimer precursor protein (Schulze et al 1993) . As GAPDH interacts with many of the polyglutamine-containing disease proteins (Burke et al 1996; Koshy et al 1996) , it would be interesting to see whether these proteins too can be localized to pathological lesions, both in diseases associated with expanded polyglutamine repeats and in other neurodegenerations. Ubiquitin is detected in both PD and AD neuronal inclusions; huntingtin is ubiquitinated and interacts with a ubiquitin-conjugating enzyme , and there is evidence for increased numbers of ubiquitin-reactive neurites in HD cortex (Cammarata et al 1993) .
The evidence thus far is consistent with huntingtin being involved in an abnormal protein inclusion in cells in areas of pathogenesis in several neurodegenerative diseases, and this is the first localization of a protein known to be involved in a neurodegenerative process in the pathological lesions of AD and PD. This observation may allow us to gain insights into the disease process in HD and in other neurodegenerative diseases. If huntingtin can aggregate, through polar zippers or other mechanisms, it may also be localized in lesions in the brain in other neurodegenerative diseases, where conformational shifts appear to lead to abnormal aggregations and pathogenesis, the most obvious example of which is the prion diseases. Figure 3 ) copurifying with microtubule-associated protein 2 (MAP2, anti-MAP2 obtained from Biogenesis, Cambridge, UK), after purification by the protocol of Keates (1984) . H=homogenate including protease inhibitors; 38K=pellet after 38 0 0 0g centrifugation; 91 K p =pellet after 91 0 0 0g centrifugation; 91 K s =supernatant after 91 0 0 0g centrifugation, from which microtubules were polymerized as in Keates (1984) ; microtubule p e l l e t =pellet obtained after 38 0 0 0g centrifugation through a 4mol/L glycerol cushion, depolymerized to load on gel. 75µg protein loaded/lane. (B) Western blot showing copurification of huntingtin with microtubules from mouse and rat brain. As above but using 100000g centrifugation prior to polymerizing the microtubules (U = unwashed microtubule pellet), which were then washed in homogenization buffer containing the concentrations of NaCl indicated on the figure. 50 µg protein/lane, except the microtubule fractions where 30 µg/lane was loaded
